The pharmacodynamics of i.v. and subcutaneous (s.c.) tinzaparin sodium compared with heparin in healthy volunteers were studied. A randomized, open-label, five-treatment, five-period-crossover study ...

Only one study evaluating the efficacy and safety of tinzaparin for the treatment of DVT has been published. In a multicenter, randomized, double-blind trial by the American- Canadian Thrombosis Study ...

Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. Background: VTE is a major cause of morbidity ...

Please provide your email address to receive an email when new articles are posted on . Extended thromboprophylaxis with weight-adjusted tinzaparin appeared safe and effective for patients following ...

According to a new study published in JAMA, treatment with low molecular-weight heparin tinzaparin did not significantly reduce recurrent venous thromboembolism (VTE) or major bleeding and overall ...

The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Tinzaparin. This inhibition accounts ...

This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The use of daily tinzaparin for 6 months ...

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared ...

Tinzaparin (Innohep (10000 iu)) is an anticoagulant, prescribed for deep vein thrombosis with or without pulmonary embolism.It works by blocking the formation of blood clots. The information provided ...